Liver enzyme induction and inhibition: implications for anaesthesia
Authors:
- 13 January 2006
- journal article
- review article
- Published by Wiley in Anaesthesia
- Vol. 61 (2) , 159-177
Abstract
Summary: Recent breakthroughs in molecular biology have enabled a reclassification of drug metabolising enzymes based on their amino acid sequence. This has led to a better understanding of drug metabolism and drug interactions. The majority of these drug metabolising enzymes may be either induced or inhibited by drugs or by extraneous substances including foodstuffs, cigarette smoke and environmental pollutants. Virtually all drugs used in anaesthesia are metabolised by either hepatic phase 1 or phase II enzymes. This review considers the classification of drug metabolising enzymes, explains the mechanisms of enzyme induction and inhibition, and also considers how the action of drugs commonly used by anaesthetists, including opioids and neuromuscular blocking drugs, may be altered by this mechanism.Keywords
This publication has 153 references indexed in Scilit:
- Methadone and FluconazoleJournal of Pain and Symptom Management, 2002
- Antiarrhythmic AgentsDrug Safety, 2000
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- Pharmacologie du tramadolDrugs, 1997
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Antidepressant Drug Interactions and the Cytochrome P450 SystemClinical Pharmacokinetics, 1995
- Pharmacokinetic Interactions of Cimetidine 1987Clinical Pharmacokinetics, 1987
- An Appraisal of Codeine as an Analgesic: Single‐Dose AnalysisThe Journal of Clinical Pharmacology, 1984
- Potentiation of opioid analgesia by H1 and H2 antagonistsLife Sciences, 1982
- Clinical Implications of Enzyme Induction and Enzyme InhibitionClinical Pharmacokinetics, 1981